Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
8.89 CNY +1.95% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. -7.01% -25.79%
05-06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
04-26 Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • Low profitability weakens the company.
  • With an enterprise value anticipated at 4.01 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-25.79% 454M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
-
MT Timing
-
LT Timing
-
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.